Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Provided By GlobeNewswire
Last update: Aug 7, 2024
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody
Claudio Dansky Ullmann, M.D. named Chief Medical Officer
Cash and cash equivalents of $101.5 million as of June 30, 2024
Read more at globenewswire.com
